湯臣集團(00258.HK)2021年純利2.83億港元 同比增長62%
格隆匯3月25日丨湯臣集團(00258.HK)公吿,截至2021年12月31日止年度,公司收入7.79億港元,同比減少16%;公司擁有人應占溢利2.83億港元,同比增長62%;每股盈利14.38港仙,宣派年度中期股息每股5.50港仙(2020年:每股5.50港仙)。
業績改善主要歸因於在回顧年度內來自物業發展及投資業務的分類溢利增加至4.56億港元(2020年:2.69億港元)。物業銷售及租賃產生的毛利均有所增長。此外,集團於年末根據適用的會計準則對位於中國上海市的投資物業作出市場估值後錄得公平值變動所產生的未變現虧損354萬港元,較2020年度錄得的虧損1233萬港元為低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.